Trial Profile
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs Guanfacine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shire
- 29 Jul 2018 Results of post hoc analysis of four studies (SPD503-301, SPD503-304, SPD503-312 and SPD503-316) published in the European Neuropsychopharmacology
- 20 Sep 2016 Results of pooled post hoc analysis of this and other trial (NCT01244490) presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
- 01 Nov 2015 Primary endpoint has been met. (Attention-Deficit Hyperactivity Disorder Rating Scale), as per an article published in the Journal of the American Academy of Child and Adolescent Psychiatry